Jorge Eduardo Cortes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6528350/publications.pdf

Version: 2024-02-01

569 papers	58,387 citations	807 118 h-index	1527 218 g-index
579 all docs	579 docs citations	579 times ranked	24616 citing authors

#	Article	IF	Citations
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
2	Dasatinib in Imatinib-Resistant Philadelphia Chromosomeâ€“Positive Leukemias. New England Journal of Medicine, 2006, 354, 2531-2541.	13.9	1,606
3	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 362, 2260-2270.	13.9	1,411
4	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosomeâ€“Positive ALL. New England Journal of Medicine, 2006, 354, 2542-2551.	13.9	1,253
5	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	0.8	1,188
6	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	0.6	1,184
7	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006, 108, 28-37.	0.6	1,117
8	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
9	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	13.9	796
10	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-NaÃ¯ve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology, 2016, 34, 2333-2340.	0.8	724
11	Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. Journal of Clinical Oncology, 2000, 18, 547-547.	0.8	706
12	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 2684-2692.	0.8	682
13	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007, 109, 52-57.	0.6	675
14	Ponatinib in Refractory Philadelphia Chromosomeâ€“Positive Leukemias. New England Journal of Medicine, 2012, 367, 2075-2088.	13.9	668
15	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Journal of Clinical Investigation, 2011, 121, 396-409.	3.9	661
16	Molecular biology of bcr-abl1â€“positive chronic myeloid leukemia. Blood, 2009, 113, 1619-1630.	0.6	591
17	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer, 2004, 101, 2788-2801.	2.0	550
18	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:. Cancer, 2006, 106, 1090-1098.	2.0	550

#	Article	IF	Citations
19	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 2004, 103, 4396-4407.	0.6	522
20	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012, 119, 1123-1129.	0.6	520
21	Acute myeloid leukaemia. Lancet, The, 2018, 392, 593-606.	6.3	512
22	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomeâ€“positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood, 2011, 118, 4567-4576.	0.6	406
23	Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology, 2012, 30, 3486-3492.	0.8	404
24	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1â€“2 study. Lancet Oncology, The, 2017, 18, 1061-1075.	5.1	402
25	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007, 109, 3207-3213.	0.6	400
26	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 2019, 33, 379-389.	3.3	396
27	Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	0.6	392
28	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	7.7	380
29	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomeâ€“positive chronic phase chronic myeloid leukemia. Blood, 2004, 103, 2873-2878.	0.6	369
30	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2014, 123, 494-500.	0.6	364
31	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosomeâ€“Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3880-3889.	0.8	361
32	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 2018, 36, 231-237.	0.8	356
33	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662.	0.6	355
34	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1856-1862.	0.8	347
35	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 2011, 117, 1141-1145.	0.6	344
36	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 2010, 116, 4422-4429.	0.6	336

#	Article	IF	Citations
37	Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. Journal of the National Cancer Institute, 2008, 100, 184-198.	3.0	334
38	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 984-997.	5.1	330
39	The effects of imatinib on pregnancy outcome. Blood, 2008, 111, 5505-5508.	0.6	328
40	Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3â€“Internal Tandem Duplication Status. Journal of Clinical Oncology, 2013, 31, 3681-3687.	0.8	321
41	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108, 1497-1503.	0.6	317
42	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 2003, 101, 473-475.	0.6	304
43	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012, 119, 1981-1987.	0.6	298
44	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 2014, 26, 428-442.	7.7	292
45	Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. Journal of Clinical Oncology, 2005, 23, 3948-3956.	0.8	290
46	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. Journal of Clinical Oncology, 2011, 29, 4417-4424.	0.8	287
47	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581.	0.6	285
48	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 2007, 110, 4005-4011.	0.6	284
49	Imatinib mesylate (STI571) therapy for Philadelphia chromosomeâ€positive chronic myelogenous leukemia in blast phase. Blood, 2002, 99, 3547-3553.	0.6	282
50	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 2012, 119, 3403-3412.	0.6	281
51	Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. Journal of Clinical Oncology, 2010, 28, 424-430.	0.8	265
52	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326.	13.9	257
53	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	6.9	257
54	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clinical Cancer Research, 2005, 11, 3425-3432.	3.2	256

#	Article	IF	Citations
55	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555.	5.1	245
56	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 2012, 118, 3123-3127.	2.0	243
57	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 2010, 116, 3830-3834.	2.0	241
58	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. Journal of Clinical Oncology, 2010, 28, 392-397.	0.8	231
59	Results of decitabine (5-aza-2?deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 2003, 98, 522-528.	2.0	230
60	The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481.	2.0	229
61	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 398-404.	0.8	227
62	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematology,the, 2015, 2, e186-e193.	2.2	227
63	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60â€ƒyears of age receiving induction therapy for acute myeloid leukaemia.. British Journal of Haematology, 2007, 136, 624-627.	1.2	223
64	Complete cytogenetic and molecular responses to interferon-?-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer, 2003, 97, 1033-1041.	2.0	219
65	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 2003, 101, 3794-3800.	0.6	215
66	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood, 2014, 123, 94-100.	0.6	214
67	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 612-621.	5.1	214
68	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, 101, 1692-1697.	0.6	210
69	Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib. Journal of Clinical Oncology, 2006, 24, 1204-1208.	0.8	210
70	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nature Communications, 2020, 11, 5327.	5.8	208
71	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 889-903.	5.1	205
72	Survival benefit with imatinib mesylate versus interferon-Î±â€“based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 2006, 108, 1835-1840.	0.6	204

#	Article	IF	Citations
73	Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin Â± All-Trans Retinoic Acid Â± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 1999, 93, 2478-2484.	0.6	201
74	Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias. Clinical Cancer Research, 2004, 10, 3371-3376.	3.2	195
75	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-Î± treatment. Blood, 2008, 111, 1039-1043.	0.6	195
76	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood, 2012, 120, 4840-4845.	0.6	193
77	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematology,the, 2018, 5, e618-e627.	2.2	190
78	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica, 2011, 96, 62-68.	1.7	185
79	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer, 2007, 109, 1133-1137.	2.0	182
80	Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2017, 18, 17.	1.3	179
81	Bosutinib versus imatinib in newly diagnosed chronicâ€phase chronic myeloid leukaemia: results from the 24â€month followâ€up of the BELA trial. British Journal of Haematology, 2015, 168, 69-81.	1.2	177
82	Result of high-dose imatinib mesylate in patients with Philadelphia chromosomeâ€"positive chronic myeloid leukemia after failure of interferon-Î±. Blood, 2003, 102, 83-86.	0.6	174
83	Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006, 81, 973-988.	1.4	171
84	Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Aloneâ€"Results of a Multicenter Phase III Study. Journal of Clinical Oncology, 2010, 28, 4207-4213.	0.8	171
85	Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia. Cancer, 2003, 97, 2218-2224.	2.0	169
86	Chronic myelogenous leukemia in nonlymphoid blastic phase. , 1999, 86, 2632-2641.		167
87	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood, 2014, 123, 2317-2324.	0.6	167
88	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica, 2014, 99, 465-473.	1.7	165
89	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosomeâ€"positive chronic-phase chronic myeloid leukemia after failure of interferon-Î±. Blood, 2004, 104, 1979-1988.	0.6	163
90	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood, 2009, 113, 3938-3946.	0.6	159

#	Article	IF	Citations
91	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Journal of Clinical Oncology, 2012, 30, 2204-2210.	0.8	158
92	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood, 2009, 113, 6322-6329.	0.6	156
93	Hyperâ€CVAD plus ponatinib versus hyperâ€CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122, 3650-3656.	2.0	156
94	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood, 2009, 113, 6315-6321.	0.6	153
95	Chronic myelogenous leukemia: A review. American Journal of Medicine, 1996, 100, 555-570.	0.6	151
96	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood, 2009, 113, 2154-2160.	0.6	151
97	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood, 2006, 108, 2811-2813.	0.6	149
98	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosomeâ€“positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 2003, 101, 97-100.	0.6	147
99	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 2021, 138, 2031-2041.	0.6	147
100	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related burkitt lymphoma/leukemia. Cancer, 2002, 94, 1492-1499.	2.0	146
101	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 2003, 101, 4714-4716.	0.6	145
102	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 2016, 127, 2742-2750.	0.6	145
103	Dasatinib in imatinibâ€resistant or â€intolerant chronicâ€phase, chronic myeloid leukemia patients: 7â€year followâ€up of study CA180â€034. American Journal of Hematology, 2016, 91, 869-874.	2.0	145
104	Phase II, multicenter, randomized trial of CPXâ€351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer, 2015, 121, 234-242.	2.0	144
105	Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2004, 22, 1287-1292.	0.8	141
106	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood, 2008, 111, 1774-1780.	0.6	140
107	Phase I/II trial of the combination of midostaurin (PKC412) and 5â€azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 276-281.	2.0	139
108	Chromosomal abnormalities in Philadelphia chromosomeâ€“negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2007, 110, 2991-2995.	0.6	138

#	Article	IF	Citations
109	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood, 2009, 114, 4361-4368.	0.6	138
110	Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine. Journal of Clinical Oncology, 1999, 17, 284-284.	0.8	135
111	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer, 2007, 109, 899-906.	2.0	134
112	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood, 2011, 118, 4541-4546.	0.6	133
113	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2014, 20, 89-97.	2.0	130
114	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia Research, 2016, 48, 84-91.	0.4	130
115	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine, 2016, 8, 355ra117.	5.8	130
116	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood, 2003, 102, 4527-4534.	0.6	129
117	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 2008, 112, 53-55.	0.6	127
118	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 897-901.	0.2	127
119	Acute lymphoblastic leukemia a comprehensive review with emphasis on biology and therapy. Cancer, 1995, 76, 2393-2417.	2.0	126
120	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, 98, 1905-1911.	2.0	124
121	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood, 2013, 121, 4867-4874.	0.6	124
122	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood, 2014, 123, 1309-1318.	0.6	124
123	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood, 2012, 120, 2573-2580.	0.6	123
124	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, 109, 248-255.	2.0	121
125	Kinase domain point mutations in Philadelphia chromosomeâ€positive acute lymphoblastic leukemia emerge after therapy with BCRâ€ABL kinase inhibitors. Cancer, 2008, 113, 985-994.	2.0	120
126	Imatinib and beyondâ€"exploring the full potential of targeted therapy for CML. Nature Reviews Clinical Oncology, 2009, 6, 535-543.	12.5	120

#	Article	IF	Citations
127	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood, 2009, 114, 2037-2043.	0.6	119
128	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood, 2016, 127, 1269-1275.	0.6	119
129	Nilotinib-Associated Vascular Events. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 337-340.	0.2	118
130	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer, 2009, 115, 2482-2490.	2.0	116
131	Current and emerging treatment options in chronic myeloid leukemia. Cancer, 2007, 109, 2171-2181.	2.0	115
132	Dasatinib in imatinibâ€resistant or imatinibâ€intolerant chronic myeloid leukemia in blast phase after 2 years of followâ€up in a phase 3 study. Cancer, 2010, 116, 3852-3861.	2.0	115
133	High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses. Journal of Clinical Oncology, 2009, 27, 4754-4759.	0.8	114
134	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer, 2009, 115, 5382-5393.	2.0	114
135	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	2.0	114
136	Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Research, 2002, 26, 881-884.	0.4	113
137	Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood, 2015, 125, 3236-3245.	0.6	113
138	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer, 2004, 100, 116-121.	2.0	111
139	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications, 2019, 10, 244.	5.8	111
140	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer, 2009, 115, 551-560.	2.0	108
141	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, 97, 2760-2766.	2.0	107
142	Staging of chronic myeloid leukemia in the imatinib era. Cancer, 2006, 106, 1306-1315.	2.0	107
143	Treatment with FLT3 inhibitor in patients with FLT3â€mutated acute myeloid leukemia is associated with development of secondary FLT3â€“tyrosine kinase domain mutations. Cancer, 2014, 120, 2142-2149.	2.0	107
144	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer, 2008, 112, 837-845.	2.0	106

#	Article	IF	Citations
145	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer, 2010, 116, 5568-5574.	2.0	104
146	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leukemia and Lymphoma, 2013, 54, 1411-1417.	0.6	104
147	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica, 2012, 97, 731-738.	1.7	103
148	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood, 2005, 105, 2281-2286.	0.6	102
149	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leukemia Research, 2010, 34, 752-756.	0.4	102
150	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€month followâ€up. American Journal of Hematology, 2014, 89, 732-742.	2.0	102
151	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematology,the, 2015, 2, e339-e346.	2.2	102
152	Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	1.2	102
153	How I treat newly diagnosed chronic phase CML. Blood, 2012, 120, 1390-1397.	0.6	100
154	Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood, 2008, 112, 516-518.	0.6	98
155	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. American Journal of Hematology, 2014, 89, 947-953.	2.0	98
156	The impact of dasatinib on pregnancy outcomes. American Journal of Hematology, 2015, 90, 1111-1115.	2.0	98
157	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or highâ€risk MDS: Phase 2 study results. American Journal of Hematology, 2018, 93, 1301-1310.	2.0	98
158	The role of Src in solid and hematologic malignancies. Cancer, 2006, 107, 1918-1929.	2.0	97
159	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research, 2002, 8, 2177-87.	3.2	97
160	Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 530-533.	0.2	96
161	Treatmentâ€free remission with firstâ€and secondâ€generation tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 346-357.	2.0	96
162	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the longâ€term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer, 2009, 115, 3709-3718.	2.0	95

#	Article	IF	Citations
163	Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood, 2015, 126, 222-232.	0.6	95
164	Sorafenib Combined with 5â€azacytidine in Older Patients with Untreated FLT3â€ITD Mutated Acute Myeloid Leukemia. American Journal of Hematology, 2018, 93, 1136-1141.	2.0	95
165	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	0.6	95
166	Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance. Journal of Clinical Oncology, 2009, 27, 3642-3649.	0.8	94
167	Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 1735-1740.	3.2	94
168	Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia. Clinical Cancer Research, 2008, 14, 4392-4399.	3.2	93
169	Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 2016, 101, 541-558.	1.7	92
170	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology,the, 2021, 8, e481-e491.	2.2	92
171	Important Therapeutic Targets in Chronic Myelogenous Leukemia. Clinical Cancer Research, 2007, 13, 1089-1097.	3.2	91
172	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer, 2011, 117, 2145-2155.	2.0	91
173	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood, 2013, 122, 641-647.	0.6	91
174	Augmented Berlinâ€Frankfurtâ€MÃ¼nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer, 2014, 120, 3660-3668.	2.0	91
175	Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer, 2006, 106, 1974-1984.	2.0	90
176	Longâ€term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology, 2016, 91, 1206-1214.	2.0	90
177	Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treatment Reviews, 2019, 76, 41-50.	3.4	90
178	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer, 2007, 109, 1556-1560.	2.0	89
179	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood, 2011, 118, 4353-4358.	0.6	89
180	High-dose chemotherapy in high-risk myelodysplastic syndrome. Cancer, 2001, 92, 1999-2015.	2.0	88

#	Article	IF	Citations
181	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Haematology, 2004, 125, 187-195.	1.2	88
182	Natural history and staging of chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 569-584.	0.9	88
183	Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 515-529.	0.2	88
184	Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clinic Proceedings, 2015, 90, 1440-1454.	1.4	88
185	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Advances, 2019, 3, 851-861.	2.5	88
186	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research, 2018, 24, 2294-2303.	3.2	87
187	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematology,the, 2015, 2, e376-e383.	2.2	86
188	Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood, 2002, 99, 2265-2267.	0.6	85
189	Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer, 2002, 94, 773-779.	2.0	85
190	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutationâ€“related imatinib failure. Blood, 2006, 108, 1421-1423.	0.6	85
191	Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer, 2003, 98, 437-457.	2.0	84
192	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 2008, 113, 1933-1952.	2.0	84
193	Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 524-531.	0.8	84
194	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research, 2002, 8, 2167-76.	3.2	84
195	Singleâ€cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3â€ITDâ€mutated AML stem/progenitor cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 346-356.	1.1	83
196	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances, 2017, 1, 1312-1323.	2.5	83
197	Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2000, 18, 3513-3521.	0.8	81
198	Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 2007, 109, 1355-1359.	2.0	81

#	Article	IF	Citations
199	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2018, 93, 213-221.	2.0	81
200	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosomeâ€positive leukemias with the T315I mutation. Cancer, 2017, 123, 2875-2880.	2.0	79
201	Clonal evolution in chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 671-684.	0.9	78
202	Survival is poorer in patients with secondary coreâ€binding factor acute myelogenous leukemia compared with de novo coreâ€binding factor leukemia. Cancer, 2009, 115, 3217-3221.	2.0	76
203	Longâ€term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosomeâ€positive leukemias treated with bosutinib. American Journal of Hematology, 2016, 91, 606-616.	2.0	76
204	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood, 2008, 112, 4839-4842.	0.6	75
205	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica, 2012, 97, 1029-1035.	1.7	74
206	Acute promyelocytic leukemia: A populationâ€based study on incidence and survival in the United States, 1975â€2008. Cancer, 2012, 118, 5811-5818.	2.0	74
207	Longâ€term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American Journal of Hematology, 2015, 90, 755-768.	2.0	72
208	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. British Journal of Cancer, 2018, 118, 1425-1433.	2.9	72
209	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood, 2011, 117, 3641-3647.	0.6	71
210	Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. Journal of Clinical Oncology, 2011, 29, 4260-4265.	0.8	71
211	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer, 2003, 98, 888-893.	2.0	69
212	Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 78-82.	0.2	69
213	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. Blood, 1999, 93, 2075-2080.	0.6	67
214	Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer, 2006, 106, 346-352.	2.0	67
215	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Cancer, 2007, 110, 340-344.	2.0	66
216	Simultaneous homoharringtonine and interferon-Î± in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer, 2002, 94, 2024-2032.	2.0	65

#	Article	IF	Citations
217	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood, 2006, 107, 480-482.	0.6	65
218	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematology,the, 2015, 2, e118-e128.	2.2	65
219	Clonal chromosomal abnormalities appearing in Philadelphia chromosomeâ€“negative metaphases during CML treatment. Blood, 2017, 130, 2084-2091.	0.6	65
220	Disruption of Wnt/Î²-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 2417-2429.	3.2	65
221	Chronic myeloid leukaemia. Lancet, The, 2021, 398, 1914-1926.	6.3	65
222	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood, 2011, 117, 1822-1827.	0.6	64
223	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemiaâ€”Comparison with historic experience. Cancer, 2005, 103, 2099-2108.	2.0	63
224	Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586.	2.0	63
225	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica, 2019, 104, 93-101.	1.7	62
226	Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosomeâ€“Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. Journal of Clinical Oncology, 2009, 27, 3659-3663.	0.8	61
227	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American Journal of Hematology, 2013, 88, 1024-1029.	2.0	61
228	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer, 2015, 121, 3894-3904.	2.0	61
229	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	0.8	61
230	Early results of lower dose dasatinib (50â€‰mg daily) as frontline therapy for newly diagnosed chronicâ€phase chronic myeloid leukemia. Cancer, 2018, 124, 2740-2747.	2.0	61
231	Third-line therapy for chronic myeloid leukemia: current status and future directions. Journal of Hematology and Oncology, 2021, 14, 44.	6.9	61
232	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood, 2011, 117, 5600-5606.	0.6	60
233	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer, 2004, 100, 2592-2597.	2.0	59
234	Longâ€term outcomes in the secondâ€line treatment of chronic myeloid leukemia. Cancer, 2011, 117, 897-906.	2.0	58

#	Article	IF	Citations
235	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood, 2012, 119, 4524-4526.	0.6	58
236	Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-Î± Failure and in Late CML-CP, Comparison with Historical Controls. Clinical Cancer Research, 2004, 10, 68-75.	3.2	56
237	Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer, 2009, 115, 2912-2921.	2.0	56
238	Synthetic tumorâ€specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease. Cancer, 2009, 115, 3924-3934.	2.0	56
239	Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 390-402.	1.4	55
240	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow-up results. Cancer, 1995, 75, 464-470.	2.0	54
241	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer, 2014, 120, 373-380.	2.0	54
242	Cardiovascular and pulmonary adverse events in patients treated with <scp>BCR</scp>â€<scp>ABL</scp> inhibitors: Data from the <scp>FDA</scp> Adverse Event Reporting System. American Journal of Hematology, 2015, 90, E66-72.	2.0	54
243	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior singleâ€agent therapy with imatinib. Cancer, 2007, 110, 1295-1302.	2.0	53
244	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematologica, 2020, 143, 567-573.	0.7	53
245	Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2005, 23, 2805-2812.	0.8	52
246	Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leukemia and Lymphoma, 2010, 51, 778-782.	0.6	52
247	FLT3 inhibitors in the treatment of acute myeloid leukemia. Cancer, 2011, 117, 3293-3304.	2.0	52
248	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica, 2015, 100, 898-904.	1.7	52
249	Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood, 2015, 126, 1699-1706.	0.6	52
250	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Scientific Reports, 2017, 7, 11253.	1.6	52
251	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. Journal of Hematology and Oncology, 2018, 11, 143.	6.9	52
252	Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer, 2007, 109, 907-914.	2.0	51

#	Article	IF	Citations
253	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer, 2010, 116, 2673-2681.	2.0	51
254	Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 155-162.e1.	0.2	51
255	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. JAMA Oncology, 2021, 7, 42.	3.4	51
256	A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 2003, 97, 1234-1241.	2.0	50
257	New Targeted Approaches in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2005, 23, 6316-6324.	0.8	50
258	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer, 2011, 117, 4869-4877.	2.0	50
259	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 2013, 122, 2807-2811.	0.6	50
260	Treatment selection after imatinib resistance in chronic myeloid leukemia. Targeted Oncology, 2009, 4, 3-10.	1.7	49
261	Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp>hiladelphia chromosomeâ€“negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	2.0	49
262	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica, 2018, 103, 1298-1307.	1.7	49
263	Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 584-591.	0.2	48
264	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.4	48
265	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 465-465.	0.6	48
266	Evolution of Therapies for Chronic Myelogenous Leukemia. Cancer Journal (Sudbury, Mass), 2011, 17, 465-476.	1.0	47
267	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with highâ€dose cytarabine and idarubicin. Cancer, 2012, 118, 2665-2673.	2.0	47
268	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer, 2017, 123, 3050-3060.	2.0	47
269	High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer, 2001, 92, 7-14.	2.0	46
270	Advanced-phase chronic myeloid leukemia. Seminars in Hematology, 2003, 40, 79-86.	1.8	46

#	Article	IF	Citations
271	Dasatinib treatment for Philadelphia chromosomeâ€positive leukemias. Cancer, 2009, 115, 1381-1394.	2.0	46
272	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. Cancer, 2011, 117, 572-580.	2.0	46
273	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). American Journal of Hematology, 2016, 91, 227-232.	2.0	46
274	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia and Lymphoma, 2007, 48, 283-289.	0.6	45
275	Firstâ€line therapy for chronic myeloid leukemia: Past, present, and future. American Journal of Hematology, 2009, 84, 287-293.	2.0	45
276	Molecular monitoring in chronic myeloid leukemia. Cancer, 2008, 112, 2112-2118.	2.0	44
277	Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronicâ€or acceleratedâ€phase chronic myeloid leukemia: Results with 24 months of followâ€up. Cancer, 2015, 121, 1637-1644.	2.0	44
278	All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer, 1994, 73, 2946-2952.	2.0	43
279	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood, 2019, 133, 2348-2351.	0.6	43
280	Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. Blood Cancer Discovery, 2020, 1, 134-145.	2.6	43
281	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood, 2014, 124, 3135-3135.	0.6	43
282	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia, 2022, 36, 1825-1833.	3.3	43
283	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 684-695.e6.	0.2	42
284	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematology,the, 2018, 5, e136-e146.	2.2	42
285	Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia. Current Molecular Medicine, 2005, 5, 615-623.	0.6	41
286	The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib Therapy. Seminars in Hematology, 2007, 44, 4-14.	1.8	41
287	Factors influencing longâ€term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology, 2016, 172, 97-110.	1.2	41
288	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 767-775.	2.0	41

#	Article	IF	Citations
289	Advanced-phase chronic myeloid leukemia. Seminars in Hematology, 2003, 40, 79-86.	1.8	41
290	AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.. Blood, 2009, 114, 636-636.	0.6	41
291	Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer, 2001, 92, 2016-2022.	2.0	40
292	Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer, 2007, 110, 2000-2006.	2.0	40
293	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer, 2010, 116, 1419-1430.	2.0	40
294	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. American Journal of Hematology, 2018, 93, 84-90.	2.0	40
295	New agents in acute myeloid leukemia and other myeloid disorders. Cancer, 2004, 100, 441-454.	2.0	39
296	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer, 2009, 115, 3935-3943.	2.0	39
297	Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?. Mayo Clinic Proceedings, 2009, 84, 161-169.	1.4	39
298	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 1451-1462.	0.6	39
299	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget, 2015, 6, 30487-30499.	0.8	39
300	Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncology, The, 2013, 14, 354-362.	5.1	38
301	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology, 2015, 90, 27-30.	2.0	38
302	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€“positive acute myeloid leukemia. Cancer, 2019, 125, 3755-3766.	2.0	38
303	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncology, 2019, 15, 3531-3545.	1.1	38
304	Disseminated Intravascular Coagulation in Adult Acute Lymphoblastic Leukemia: Frequent Complications with Fibrinogen Levels Less than 100 mg/dl. Leukemia and Lymphoma, 1996, 21, 85-92.	0.6	37
305	Targeted therapy in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 2008, 8, 99-110.	1.1	37
306	Clinical impact of dose reductions and interruptions of secondâ€generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. British Journal of Haematology, 2010, 150, 303-312.	1.2	37

#	Article	IF	Citations
307	A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 223-230.	0.2	37
308	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439.	2.0	37
309	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2017, 18, 1618.	1.8	37
310	Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Blood, 2020, 136, 47-50.	0.6	37
311	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosomeâ€"positive leukemias. Blood, 2008, 112, 5190-5192.	0.6	36
312	A phase 1â€2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2011, 117, 1236-1244.	2.0	36
313	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34â€positive compartment. Cancer, 2012, 118, 5283-5292.	2.0	36
314	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine, 2015, 13, 294.	1.8	36
315	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with allâ€trans retinoic acid and arsenic trioxide. British Journal of Haematology, 2015, 171, 471-477.	1.2	36
316	Firstâ€line treatment selection and early monitoring patterns in chronic phaseâ€chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2017, 92, 1214-1223.	2.0	36
317	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer, 2004, 100, 2396-2402.	2.0	35
318	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leukemia and Lymphoma, 2014, 55, 2879-2886.	0.6	35
319	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia, 2020, 34, 2064-2073.	3.3	35
320	Accelerated and blastic phases of chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 753-774.	0.9	34
321	Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2008, 9, 1029-1037.	0.9	34
322	Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. Current Treatment Options in Oncology, 2013, 14, 127-143.	1.3	34
323	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematology,the, 2016, 3, e581-e591.	2.2	34
324	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2021, 106, 2121-2130.	1.7	34

#	Article	IF	Citations
325	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opinion on Investigational Drugs, 2007, 16, 679-687.	1.9	33
326	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Reviews, 2014, 28, 179-187.	2.8	33
327	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1.	6.9	33
328	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864.	2.0	33
329	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	2.0	32
330	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronicâ€phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2019, 94, 46-54.	2.0	32
331	Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€1 or higherâ€risk myelodysplastic syndrome. British Journal of Haematology, 2021, 195, 378-387.	1.2	32
332	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Investigational New Drugs, 1999, 17, 89-95.	1.2	31
333	Advances in the Therapy of Chronic Idiopathic Myelofibrosis. Oncologist, 2006, 11, 929-943.	1.9	31
334	Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the â€œBestâ€•Therapy?. Current Oncology Reports, 2010, 12, 302-313.	1.8	31
335	Monitoring molecular response in chronic myeloid leukemia. Cancer, 2011, 117, 1113-1122.	2.0	31
336	Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 286-296.	0.2	31
337	Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action. Leukemia and Lymphoma, 2004, 45, 2187-2195.	0.6	30
338	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. Journal of Hematology and Oncology, 2015, 8, 32.	6.9	30
339	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer, 2016, 122, 238-248.	2.0	30
340	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evidence, 2010, 4, 207.	4.7	29
341	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCRâ€ABL kinase domain mutation T315I. Cancer, 2010, 116, 3631-3637.	2.0	29
342	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica, 2013, 98, 1686-1688.	1.7	29

#	Article	IF	Citations
343	New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance. Seminars in Hematology, 2007, 44, 25-31.	1.8	28
344	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leukemia and Lymphoma, 2015, 56, 120-127.	0.6	28
345	Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera â€“ single center experience. Leukemia and Lymphoma, 2016, 57, 237-239.	0.6	28
346	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology, 2020, 13, 92.	6.9	28
347	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1288-1295.	2.0	28
348	Beyond chronic myelogenous leukemia. Cancer, 2004, 100, 2064-2078.	2.0	27
349	Emerging Safety Issues with Imatinib and Other Abl Tyrosine Kinase Inhibitors. Clinical Lymphoma and Myeloma, 2007, 7, S105-S112.	1.4	27
350	Practical Management of Toxicities Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Clinical Lymphoma and Myeloma, 2008, 8, S82-S88.	1.4	27
351	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leukemia and Lymphoma, 2008, 49, 1399-1402.	0.6	27
352	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2014, 23, 943-954.	1.9	27
353	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773.	2.0	27
354	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline secondâ€•and thirdâ€generation tyrosine kinase inhibitors. Cancer Medicine, 2018, 7, 5457-5469.	1.3	27
355	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology, 2021, 100, 1181-1194.	0.8	27
356	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. Blood, 2020, 136, 41-42.	0.6	27
357	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 2003, 97, 2225-2228.	2.0	26
358	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Current Opinion in Oncology, 2006, 18, 578-583.	1.1	26
359	Molecular targeted therapy in acute myeloid leukemia. Hematology, 2012, 17, s59-s62.	0.7	26
360	New treatment for acute myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2015, 16, 95-106.	0.9	26

#	Article	IF	Citations
361	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 213-222.e2.	0.2	26
362	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395.	2.0	26
363	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer, 2012, 118, 418-427.	2.0	25
364	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 152-162.	0.2	25
365	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. International Journal of Hematology, 2019, 109, 545-552.	0.7	25
366	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	2.0	25
367	Leukemia cells eat their VEGFtables. Blood, 2002, 100, 4256-4256.	0.6	24
368	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer, 2005, 104, 777-780.	2.0	24
369	Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 477-484.	0.2	24
370	Ponatinib in Philadelphia Chromosomeâ€"Positive Leukemias. New England Journal of Medicine, 2014, 370, 577-577.	13.9	24
371	Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. Expert Opinion on Drug Delivery, 2015, 12, 1107-1120.	2.4	24
372	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine, 2019, 8, 6559-6565.	1.3	24
373	Sudden blastic transformation in treatmentâ€free remission chronic myeloid leukaemia. British Journal of Haematology, 2019, 187, 543-545.	1.2	24
374	Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia. Seminars in Oncology, 2008, 35, S1-S17.	0.8	23
375	Current patient management of chronic myeloid leukemia in Latin America. Cancer, 2010, 116, 4991-5000.	2.0	23
376	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemotherapy and Pharmacology, 2013, 71, 1599-1607.	1.1	23
377	Prediction for sustained deep molecular response of BCRâ€ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer, 2018, 124, 1160-1168.	2.0	23
378	Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 137.	6.9	23

#	Article	IF	Citations
379	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. American Journal of Hematology, 2021, 96, 1000-1007.	2.0	23
380	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. Blood, 2019, 134, 231-231.	0.6	23
381	Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),. Blood, 2011, 118, 3785-3785.	0.6	23
382	New Strategies in Chronic Myeloid Leukemia. International Journal of Hematology, 2006, 83, 289-293.	0.7	22
383	Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome. Clinical Cancer Research, 2008, 14, 509-514.	3.2	22
384	Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Review of Anticancer Therapy, 2013, 13, 1433-1452.	1.1	22
385	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica, 2017, 102, 519-528.	1.7	22
386	Phase 1 study of combinatorial sorafenib, <scp>Gâ€CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3â€ITD</scp>â€mutated acute myelogenous leukemia patients. American Journal of Hematology, 2020, 95, 1296-1303.	2.0	22
387	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer Journal, 2021, 11, 60.	2.8	22
388	Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncology, 2008, 4, 611-621.	1.1	21
389	Imatinib frontâ€line therapy is safe and effective in patients with chronic myelogenous leukemia with preâ€existing liver and/or renal dysfunction. Cancer, 2010, 116, 3152-3159.	2.0	21
390	Current eventâ€free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer, 2011, 117, 327-335.	2.0	21
391	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leukemia Research, 2015, 39, 822-827.	0.4	21
392	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1589-1599.	1.2	21
393	How to manage CML patients with comorbidities. Blood, 2020, 136, 2507-2512.	0.6	21
394	Longâ€term results of frontline dasatinib in chronic myeloid leukemia. Cancer, 2020, 126, 1502-1511.	2.0	21
395	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer, 2001, 92, 2501-2507.	2.0	20
396	Third-Generation Tyrosine Kinase Inhibitors and Beyond. Seminars in Hematology, 2010, 47, 371-380.	1.8	20

#	Article	IF	Citations
397	The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 302-306.	0.2	20
398	Salvage therapy using <scp>FLT</scp>3 inhibitors may improve longâ€term outcome of relapsed or refractory <scp>AML</scp> in patients with <scp>FLT</scp>3â€<scp>ITD</scp>. British Journal of Haematology, 2013, 161, 659-666.	1.2	20
399	Clinical characteristics of Philadelphia positive Tâ€cell lymphoid leukemiasâ€"(De novo and blast phase) Tj ETQq1 1 0.784314 rgBT /Ov	2.0	20
400	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Blood, 2020, 136, 51-52.	0.6	20
401	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	Article	IF	Citations
415	A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. Journal of Hematology and Oncology, 2022, 15, .	6.9	18
416	Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia. International Journal of Hematology, 2004, 79, 411-419.	0.7	17
417	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Research, 2005, 29, 649-652.	0.4	17
418	The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer, 2008, 113, 1338-1343.	2.0	17
419	Omacetaxine mepesuccinate (synribo) â€“ newly launched in chronic myeloid leukemia. Expert Opinion on Pharmacotherapy, 2013, 14, 1977-1986.	0.9	17
420	Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2014, 32, 3077-3077.	0.8	17
421	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology, 2015, 90, 1065-1070.	2.0	17
422	NPM1mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information inNPM1â€mutated acute myeloid leukemia. American Journal of Hematology, 2019, 94, E158-E160.	2.0	17
423	Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. American Journal of Hematology, 2021, 96, 493-507.	2.0	17
424	Overcoming drug resistance in chronic myeloid leukemia. Current Opinion in Hematology, 2006, 13, 79-86.	1.2	16
425	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer, 2011, 117, 5085-5093.	2.0	16
426	Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica, 2015, 100, e494-e495.	1.7	16
427	Chronic myeloid leukemia: sequencing of TKI therapies. Hematology American Society of Hematology Education Program, 2016, 2016, 164-169.	0.9	16
428	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of Hematology, 2017, 96, 1303-1313.	0.8	16
429	Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. Mayo Clinic Proceedings, 2009, 84, 161-9.	1.4	16
430	Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2014, 32, 7027-7027.	0.8	16
431	CMML: a biologically distinct myeloproliferative disease. Psychophysiology, 2003, 2, 202-8.	1.1	16
432	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews, 2022, 56, 100968.	2.8	16

#	Article	IF	Citations
433	Farnesyltransferase Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Clinical Lymphoma and Myeloma, 2003, 4, S30-S35.	2.1	15
434	The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 421-426.	0.2	15
435	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer, 2018, 18, 359.	1.1	15
436	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 509-515.e1.	0.2	15
437	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 631-640.	0.6	15
438	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia treated with hyperâ€CVAD and dasatinib. Cancer, 2021, 127, 2641-2647.	2.0	15
439	Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. Blood, 2019, 134, 674-674.	0.6	15
440	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. Blood, 2019, 134, 1638-1638.	0.6	15
441	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood, 2015, 126, 2546-2546.	0.6	15
442	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica, 2021, 106, 2853-2858.	1.7	15
443	Longâ€term prognostic impact of the use of erythropoieticâ€stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer, 2011, 117, 982-991.	2.0	14
444	Treatment options for chronic myeloid leukemia. Expert Opinion on Pharmacotherapy, 2012, 13, 815-828.	0.9	14
445	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer, 2016, 122, 3336-3343.	2.0	14
446	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. JCO Oncology Practice, 2021, 17, e497-e505.	1.4	14
447	Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Current Oncology Reports, 2021, 23, 91.	1.8	14
448	Longâ€term results of a phase 2 trial of nilotinib 400Âmg twice daily in newly diagnosed patients with chronicâ€phase chronic myeloid leukemia. Cancer, 2020, 126, 1448-1459.	2.0	14
449	Clinical activity of tipifarnib in hematologic malignancies. Expert Opinion on Investigational Drugs, 2007, 16, 381-392.	1.9	13
450	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Science, 2010, 101, 2005-2010.	1.7	13

#	Article	IF	Citations
451	A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. European Journal of Cancer Care, 2013, 22, 605-611.	0.7	13
452	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. Journal of Clinical Pharmacology, 2020, 60, 605-616.	1.0	13
453	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal of Hematology, 2021, 113, 92-99.	0.7	13
454	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Advances, 2021, 5, 1719-1728.	2.5	13
455	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. Blood, 2018, 132, 790-790.	0.6	13
456	Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.. Journal of Clinical Oncology, 2018, 36, 7002-7002.	0.8	13
457	Financial distress among breast cancer survivors. Current Cancer Reports, 2020, 2, 48-53.	1.0	13
458	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opinion on Investigational Drugs, 2008, 17, 1127-1136.	1.9	12
459	Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2014, 23, 265-272.	1.9	12
460	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2015, 21, 552-558.	2.0	12
461	A second-generation TKI should always be used as initial therapy for CML. Blood Advances, 2018, 2, 3653-3655.	2.5	12
462	Survivorship in AML â€“ a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia and Lymphoma, 2020, 61, 3120-3127.	0.6	12
463	How to manage CML patients with comorbidities. Hematology American Society of Hematology Education Program, 2020, 2020, 237-242.	0.9	12
464	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomeâ€'positive leukemias. Leukemia Research, 2021, 111, 106690.	0.4	12
465	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?. Current Oncology Reports, 2009, 11, 337-345.	1.8	11
466	Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. Clinical Lymphoma and Myeloma, 2009, 9, S261-S265.	1.4	11
467	Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opinion on Pharmacotherapy, 2012, 13, 2381-2395.	0.9	11
468	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leukemia and Lymphoma, 2018, 59, 1312-1322.	0.6	11

#	Article	IF	Citations
469	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. Leukemia and Lymphoma, 2019, 60, 2384-2393.	0.6	11
470	Treatment patterns and deep molecular response in chronic phase â€“ chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. Leukemia and Lymphoma, 2020, 61, 98-107.	0.6	11
471	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leukemia and Lymphoma, 2021, 62, 909-917.	0.6	11
472	Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.. Journal of Clinical Oncology, 2020, 38, 7502-7502.	0.8	11
473	Knowledge of prostate cancer among African American men: A systematic review. Prostate, 2021, 81, 202-213.	1.2	11
474	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targeted Oncology, 2006, 1, 186-196.	1.7	10
475	The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica, 2013, 98, e131-e131.	1.7	10
476	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e871-e882.	0.2	10
477	Longâ€term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosomeâ€“positive leukemia resistant or intolerant to prior therapy. European Journal of Haematology, 2021, 106, 808-820.	1.1	10
478	Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing â‰¥ 3 Prior TKI Therapies: Initial Safety and Efficacy. Blood, 2019, 134, 4158-4158.	0.6	10
479	Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.. Journal of Clinical Oncology, 2020, 38, 7509-7509.	0.8	10
480	Current Practices in the Management of Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 48-54.	0.2	9
481	Numb chin syndrome by precursor B acute lymphoblastic leukemia. American Journal of Hematology, 2014, 89, 860-861.	2.0	9
482	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCRâ€“ABL kinase domain mutations. International Journal of Hematology, 2018, 107, 689-695.	0.7	9
483	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. Journal of the National Cancer Institute, 2022, 114, 160-164.	3.0	9
484	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph +) Tj ETQq0 0.0 rgBT /Overlock 10	0.6	9
485	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. Blood, 2007, 110, 283-283.	0.6	9
486	Investigational strategies in chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 619-639.	0.9	8

#	Article	IF	Citations
487	Evaluation of thel-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2007, 16, 547-557.	1.9	8
488	Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure. Clinical Lymphoma and Myeloma, 2009, 9, S272-S279.	1.4	8
489	Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2240-2242.	0.6	8
490	The clinical impact of time to response in de novo acceleratedâ€phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1127-1134.	2.0	8
491	Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health â€œAll of Usâ€•Research Program. Cancer Medicine, 2021, 10, 3646-3654.	1.3	8
492	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 0 0 rgBT /Overlock 1	0.6	8
493	Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. Journal of Clinical Oncology, 2017, 35, 7012-7012.	0.8	8
494	Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. British Journal of Haematology, 2004, 124, 727-738.	1.2	7
495	Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica, 2013, 98, e141-e142.	1.7	7
496	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820.	0.6	7
497	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia, 2020, 34, 2914-2924.	3.3	7
498	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 338-344.	0.2	7
499	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. Blood, 2018, 132, 3005-3005.	0.6	7
500	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) Tj ETQq0 0 0 rgBT /Overlock 1	0.8	7
501	del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genetics and Cytogenetics, 2009, 192, 18-23.	1.0	6
502	Does pretreatment fluorescencein situhybridization forBCRâ€“ABLpredict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. Leukemia and Lymphoma, 2011, 52, 1010-1016.	0.6	6
503	Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 693-699.	0.2	6
504	Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy, 2015, 21, 663-667.	0.8	6

#	Article	IF	Citations
505	A qualityâ€adjusted survival time without symptoms or toxicities analysis of glasdegib plus lowâ€dose cytarabine versus lowâ€dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer, 2020, 126, 4315-4321.	2.0	6
506	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. Cancer Chemotherapy and Pharmacology, 2020, 86, 451-459.	1.1	6
507	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia â€“ a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	0.6	6
508	Financial assistance programs for cancer patients. Current Cancer Reports, 2021, 3, 119-123.	1.0	6
509	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7â€‰+â€‰3 in older adults with newly diagnosed high-risk/secondary AML. Journal of Hematology and Oncology, 2021, 14, 110.	6.9	6
510	Pregnancy Outcomes in Patients Treated with Bosutinib. Blood, 2018, 132, 1729-1729.	0.6	6
511	Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).. Journal of Clinical Oncology, 2015, 33, 7047-7047.	0.8	6
512	Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.. Journal of Clinical Oncology, 2017, 35, 7002-7002.	0.8	6
513	Treatment-free remission in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2019, 17, 686-696.	0.3	6
514	Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. International Journal of Hematology, 2022, 115, 838-851.	0.7	6
515	Optimizing Treatment with Bcr-Abl Tyrosine Kinase Inhibitors in Philadelphia Chromosomeâ€”Positive Chronic Myeloid Leukemia: Focus on Dosing Schedules. Clinical Lymphoma and Myeloma, 2008, 8, S75-S81.	1.4	5
516	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica, 2016, 101, e324-e327.	1.7	5
517	Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2017, 58, 722-725.	0.6	5
518	Addressing financial toxicity in oncology care. Journal of Hospital Management and Health Policy, 2021, 5, 32-32.	0.4	5
519	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. Blood, 2007, 110, 577-577.	0.6	5
520	Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy,. Blood, 2011, 118, 3771-3771.	0.6	5
521	Optimizing management of acute leukemia in community centers and when to refer. Hematology American Society of Hematology Education Program, 2020, 2020, 123-128.	0.9	5
522	Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6 Suppl 2, S22-S30.	2.3	5

#	Article	IF	Citations
523	Management of Patients with Newly Diagnosed Chronic Myeloid Leukemia: Opportunities and Challenges. Clinical Lymphoma and Myeloma, 2007, 7, S51-S57.	1.4	4
524	Standard Management of Patients With Chronic Myeloid Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S382-S390.	1.4	4
525	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia and Lymphoma, 2010, 51, 1478-1484.	0.6	4
526	Molecular Resistance: An Early Indicator for Treatment Change?. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 79-87.	0.2	4
527	Reply to K.R. Hoffman. Journal of Clinical Oncology, 2017, 35, 567-568.	0.8	4
528	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer, 2017, 123, 609-616.	2.0	4
529	Philadelphia chromosomeâ€negative acute leukemia in patients with chronic myeloid leukemia. American Journal of Hematology, 2019, 94, E256-E259.	2.0	4
530	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S228-S229.	0.2	4
531	Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S231.	0.2	4
532	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190.	2.0	4
533	Clinical value of event-free survival in acute myeloid leukemia. Blood Advances, 2020, 4, 1690-1699.	2.5	4
534	Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 2733-2733.	0.6	4
535	Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosomeâ€'Positive Chronic Myeloid Leukemia. Blood, 2016, 128, 1921-1921.	0.6	4
536	Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.. Journal of Clinical Oncology, 2018, 36, TPS7073-TPS7073.	0.8	4
537	Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clinical Investigation, 2013, 3, 1127-1138.	0.0	3
538	Problems in living among breast cancer survivors. Current Cancer Reports, 2021, 3, 101-109.	1.0	3
539	Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. , 1997, 80, 396-400.		2
540	Introduction to a review series on adolescent and young adult malignant hematology:. Blood, 2018, 132, 345-346.	0.6	2

#	Article	IF	Citations
541	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia and Lymphoma, 2019, 60, 3172-3180.	0.6	2
542	Chronic Myeloid Leukemia. , 2020, , 1836-1849.e2.		2
543	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 2020, 61, 3287-3305.	0.6	2
544	The Care of the Leukemic Patients in Times of SARS-CoV-2. Current Oncology Reports, 2021, 23, 114.	1.8	2
545	Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML). Blood, 2019, 134, 382-382.	0.6	2
546	Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis. Blood, 2019, 134, 2610-2610.	0.6	2
547	Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for		

#	Article	IF	Citations
559	Investigational Agents in Myeloid Disorders. Advances in Pharmacology, 2004, 51, 59-97.	1.2	0
560	Optimal Therapy for Chronic Myeloid Leukemia Blast Crisis: Current Concepts. Clinical Leukemia, 2006, 1, 87-94.	0.2	0
561	Keeping up with rapid change. Current Hematologic Malignancy Reports, 2006, 1, 1-1.	1.2	0
562	Applying Cytogenetic and Molecular Information in the Clinic: Implications for the Treatment of Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S14-S19.	0.2	0
563	Chronic myeloid leukemia: The race is yet to be won. Cmaj, 2012, 184, 857-858.	0.9	0
564	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Opinion on Orphan Drugs, 2013, 1, 607-623.	0.5	0
565	New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 33-39.	0.6	0
566	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. Hematologic Malignancies, 2021, , 61-76.	0.2	0
567	New Agents in Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 501-512.	2.3	0
568	Chronic Myeloid Leukemia: Pathophysiology and Therapeutics. , 2010, , 139-153.		0
569	Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results.. Journal of Clinical Oncology, 2020, 38, 1574-1574.	0.8	0